NCT04179734View on ClinicalTrials.gov

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions
Hypoactive Sexual Desire Disorder
Interventions
DRUG

Bremelanotide

Melanocortin-4 receptor agonist subcutaneous injection.

DRUG

Placebo

Placebo subcutaenous injection.

Trial Locations (1)

W12 0HS

Imperial College Healthcare NHS Trust, London

Sponsors
All Listed Sponsors
collaborator

AMAG Pharmaceuticals, Inc.

INDUSTRY

lead

Imperial College Healthcare NHS Trust

OTHER